ASEP Medical Holdings Inc.

OTCPK:SEPS.F Stock Report

Market Cap: US$2.7m

ASEP Medical Holdings Valuation

Is SEPS.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SEPS.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SEPS.F's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SEPS.F's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SEPS.F?

Key metric: As SEPS.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SEPS.F. This is calculated by dividing SEPS.F's market cap by their current revenue.
What is SEPS.F's PS Ratio?
PS Ratio22.7x
SalesCA$169.12k
Market CapCA$3.84m

Price to Sales Ratio vs Peers

How does SEPS.F's PS Ratio compare to its peers?

The above table shows the PS ratio for SEPS.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.3x
RSLS ReShape Lifesciences
0.3xn/aUS$2.8m
AVGR Avinger
0.4x30.2%US$2.7m
TLIS Talis Biomedical
7.6xn/aUS$3.1m
NAOV NanoVibronix
0.8xn/aUS$2.6m
SEPS.F ASEP Medical Holdings
22.7xn/aUS$3.8m

Price-To-Sales vs Peers: SEPS.F is expensive based on its Price-To-Sales Ratio (22.7x) compared to the peer average (2.3x).


Price to Sales Ratio vs Industry

How does SEPS.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

50 CompaniesPrice / SalesEstimated GrowthMarket Cap
INGN Inogen
0.7x4.2%US$223.42m
ARAY Accuray
0.4x5.5%US$194.09m
NVRO Nevro
0.4x2.5%US$169.37m
KEQU Kewaunee Scientific
0.6xn/aUS$125.50m
SEPS.F 22.7xIndustry Avg. 3.3xNo. of Companies50PS02.85.68.411.214+
50 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SEPS.F is expensive based on its Price-To-Sales Ratio (22.7x) compared to the US Medical Equipment industry average (3.3x).


Price to Sales Ratio vs Fair Ratio

What is SEPS.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SEPS.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio22.7x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate SEPS.F's Price-To-Sales Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies